Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: physician's standard of care Clear all
Completed Not applicable Interventional Results available

Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)

NCT03176173
View directory record Official record
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy)
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 10, 2026, 9:14 PM EDT
Recruiting Phase 2 Interventional

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

NCT06627751
View directory record Official record
Conditions
Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Mezigdomide, Carfilzomib, Dexamethasone, Echocardiography, Positron Emission Tomography, Computed Tomography, Computed Tomography Assisted Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection
Biological · Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Recruiting Phase 3 Interventional

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Ifinatamab deruxtecan, Topotecan, Amrubicin, Lurbinectedin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
30
States / cities
Springdale, Arkansas • Fullerton, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional Results available

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

NCT04364048
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Carcinoma
Interventions
Induction Durvalumab, Chemotherapy, Radiation, Consolidation durvalumab
Drug · Radiation
Lead sponsor
Rachel Sanborn
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Wichita, Kansas • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 10, 2026, 9:14 PM EDT
Completed Phase 1 Interventional

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006
View directory record Official record
Conditions
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Ibrutinib
Other · Drug
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 10, 2026, 9:14 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Zanidatamab, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
21
States / cities
Duarte, California • Lone Tree, Colorado • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

NCT02500043
View directory record Official record
Conditions
Refractory Metastatic Gastric Cancer
Interventions
TAS-102, Placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
24
States / cities
Gilbert, Arizona • Berkeley, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 10, 2026, 9:14 PM EDT
Not listed Phase 2 Interventional

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

NCT04197687
View directory record Official record
Conditions
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine
Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
30
States / cities
Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 10, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional Results available

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

NCT04849364
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Capecitabine, Talazoparib, Pembrolizumab, Inavolisib
Drug
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 10, 2026, 9:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Abemaciclib in Recurrent Glioblastoma

NCT02981940
View directory record Official record
Conditions
Glioblastoma
Interventions
Abemaciclib, Surgery
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Completed Not applicable Interventional

Hypertension With Unsatisfactory Sleep Health

NCT02508129
View directory record Official record
Conditions
Insomnia, Hypertension
Interventions
Brief Behavioral Treatment for Insomnia, Sleep Healthy Using the Internet, Enhanced Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 10, 2026, 9:14 PM EDT
Recruiting Phase 2 Interventional

Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]

NCT06713382
View directory record Official record
Conditions
Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
Interventions
Pleural Saline Irrigation
Combination Product
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

NCT01215344
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VELCADE, Lenalidomide, Dexamethasone, DVT prophylaxis, Bisphosphonates, Liposomal doxorubicin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Memphis, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 10, 2026, 9:14 PM EDT
Completed No phase listed Observational

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

NCT00532740
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Yttrium Y 90 glass microspheres
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 10, 2026, 9:14 PM EDT
Completed Not applicable Interventional Results available

Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction

NCT01208974
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma
Interventions
Nipple-Sparing Mastectomy, Breast Reconstruction, Axillary Surgery, Prophylactic Nipple-Areolar Complex RT
Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Recruiting Not applicable Interventional

Patient-Centered Decision Support for Eosinophilic Esophagitis

NCT06817213
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
General education control, Decision support tool
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Fulvestrant, Standard Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
55
States / cities
Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 10, 2026, 9:14 PM EDT
Active, not recruiting Phase 3 Interventional

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

NCT03769506
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
ASP-1929 Photoimmunotherapy, Physician's Choice SOC
Combination Product · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 10, 2026, 9:14 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The STandard Versus ImAging SuBstrate Aided Ablation in Severe Left VEntricular Dysfunction VT.

NCT05828667
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 10, 2026, 9:14 PM EDT
Terminated Phase 4 Interventional Results available

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

NCT00712270
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 10, 2026, 9:14 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703
View directory record Official record
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

NCT02205762
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin
Drug · Procedure · Biological
Lead sponsor
North American Consortium for Histiocytosis
Other
Eligibility
Up to 18 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Active, not recruiting Not applicable Interventional

Time-Restricted Eating for Type II Diabetes: TRE-T2D

NCT05365529
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Time Restricted Feeding, Diabetes type2
Interventions
Time-Restricted Eating, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 10, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

NCT01857817
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
VT-122, Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 10, 2026, 9:14 PM EDT